CDK4/6 Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have transformed hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer treatment.
• The concept of a uniform "class effect" for these inhibitors is being replaced by an understanding of agent-specific profiles.

Purpose of the Study:

• To analyze the distinct efficacy of CDK4/6 inhibitors in early and metastatic breast cancer.
• To categorize resistance mechanisms to CDK4/6 inhibitors.
• To explore emerging strategies for overcoming treatment resistance.

Main Methods:

• Comparative analysis of clinical trial data for abemaciclib, ribociclib, and palbociclib in early and metastatic breast cancer.
• Classification of resistance mechanisms into target-driven and bypass-driven categories.
• Review of novel therapeutic strategies targeting resistance pathways.

Main Results:

• Adjuvant abemaciclib and ribociclib improve invasive disease-free survival in high-risk early breast cancer, while palbociclib does not.
• In metastatic breast cancer, all three agents improve progression-free survival with endocrine therapy; ribociclib and potentially abemaciclib show overall survival benefits.
• Resistance mechanisms include target-driven alterations (e.g., RB1 loss, CDK6 amplification) and bypass-driven pathways (e.g., ESR1 mutations, PI3K/AKT activation).

Conclusions:

• CDK4/6 inhibitors are not interchangeable, with differing impacts on survival outcomes based on the agent and disease stage.
• Understanding resistance mechanisms is crucial for developing rational sequencing and combinatorial treatment strategies.
• Future advancements require intelligent use of current therapies, refined biomarker selection, and improved global access to treatment.